Interaction Checker
Potential Interaction
Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF)
Vilanterol
Quality of Evidence: Very Low
Summary:
Coadministration has not been studied. Vilanterol is metabolized by CYP3A4 and is a substrate of P-gp. Coadministration with ketoconazole (an inhibitor of CYP3A4 and P-gp) for 7 days increased vilanterol exposure by 65% but this did not increase the occurrence of beta-adrenergic agonist related systemic effects (i.e., heart rate, blood pressure or significant QT interval prolongation) and did not change blood potassium or blood glucose compared to vilanterol alone. A similar magnitude of interaction may occur with elvitegravir/cobicistat. Although the ketoconazole-vilanterol interaction study showed no adverse cardiovascular effects when coadministered for a duration of 7 days, the American product label for vilanterol recommends caution when coadministering vilanterol with a strong CYP3A4 inhibitor as increased cardiovascular adverse effects may occur. Monitor for side effects. Emtricitabine and tenofovir alafenamide do not interfere with vilanterol metabolism.
Description:
View all available interactions with Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (EVG/c/FTC/TAF) by clicking here.
No Version Present
Copyright © 2024 The University of Liverpool. All rights reserved.